Tag: HPV16
Transgene presents immunological data demonstrating that TG4001, a novel therapeutic cancer vaccine, can induce T-cell responses against HPV16 antigens in the ongoing Phase II trial at ASCO 2023 – 06/05/2023 at 07:30
TG4001 can induce de novo immune responses against HPV16 antigens E6 and E7 in patients with advanced HPV16-positive anogenital cancers Patients with complete objective response showed strong vaccine-induced immunoreactivity Transgene…
ASCO 2023 – Transgene presents immunological data demonstrating that TG4001, an innovative therapeutic cancer vaccine, can induce immune responses against HPV16 antigens in the ongoing Phase II trial – 06/05/2023 at 07:30
TG4001 can induce de novo immune responses against HPV16 E6 and E7 antigens in patients with HPV16-positive anogenital cancers Patients with a complete clinical response also have strong immunoreactivity induced…